Deans' stroke musings: Liraglutide Reduces Risk of Stroke, Cardiovascular Death in Patients With Diabetes

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, June 21, 2016

Liraglutide Reduces Risk of Stroke, Cardiovascular Death in Patients With Diabetes

In case you have diabetes and your doctor doesn't tell you about this in the next month.
http://dgnews.docguide.com/liraglutide-reduces-risk-stroke-cardiovascular-death-patients-diabetes?overlay=2&nl_ref=newsletter&pk_campaign=newsletter
Liraglutide safely and effectively decreases the overall risk of myocardial infarction (MI), stroke or cardiovascular death in patients with type 2 diabetes, according to a study published in the New England Journal of Medicine.
Liraglutide was also associated with a reduction in kidney disease and death from all causes.
“This is the first diabetes drug that has shown across-the-board benefits for cardiovascular diseases, and this suggests it plays a role in treating atherosclerosis, which is what leads to heart attacks and strokes,” said senior author John Buse, MD, Diabetes Care Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
The Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results (LEADER) study randomised 9,430 adult patients with type 2 diabetes who were at high risk of heart disease to receive liraglutide or other diabetes medications to control their blood sugar.
Both groups of patients were prescribed medications to address associated health problems, such as high blood pressure and high cholesterol.
The trial lasted more than 3 years. In the end, liraglutide was associated with a 13% lower overall risk of having a MI or stroke, or of dying from cardiovascular cause; a 22% lower risk of cardiovascular mortality; a 15% lower risk of all-cause mortality; and a 22% lower risk of new evidence of advanced kidney disease
“This changes the whole conversation about treating diabetes,” said Dr. Buse said. “To date, people have taken diabetes drugs to lower blood sugar. Now we can say that they should take liraglutide to prevent or delay the worst things that occur commonly in diabetes -- heart attacks, strokes, advanced kidney disease, and death.”
SOURCE: University of North Carolina Health Care System